Abstract
In the Netherlands, patients with early-stage HR+/HER2-, N0 breast cancer may receive adjuvant chemotherapy in conjunction with surgery. Clinical data shows that chemotherapy does not always contribute to improved survival and is associated with relatively high healthcare expenditure and toxicity. Gene expression tests such as the Oncotype DX® test can support physicians in decision-making regarding whether chemotherapy provides added clinical benefit for the patient. This cost-consequence model aims to analyze the economic impact of testing with different gene expression tests and no testing in the Netherlands, for patients with early-stage breast cancer.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
